Formulation and pharmacology of long-acting cabotegravir.

Authors:
Trezza C; Ford SL; Spreen W; Pan R; Piscitelli S.

Journal:
Curr Opin HIV AIDS

Publication Year: 2015

DOI:
10.1097/COH.0000000000000168

PMCID:
PMC5638427

PMID:
26049948

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Curr Opin HIV AIDS

Abbreviation: Curr Opin HIV AIDS

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Acquired Immunodeficiency Syndrome

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Accelerating HIV vaccine development through meaningful engagement of local scientists and communit…
Chinyenze K; Nduati E; Muturi-Kioi V. (2023) - Transparency Score: 3/6
Defining multimorbidity in people with HIV - what matters most?
Sukumaran L; Sabin CA. (2023) - Transparency Score: 3/6
Discovery medicine - the HVTN's iterative approach to developing an HIV-1 broadly neutralizing vacc…
Martin TM; Robinson ST; Huang Y. (2023) - Transparency Score: 3/6
'Immunization during ART and ATI for HIV-1 vaccine discovery/development'.
Stamatatos L. (2023) - Transparency Score: 3/6
Impact of early antiretroviral therapy, early life immunity and immune sex differences on HIV disea…
Herbert NG; Goulder PJR. (2023) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
2/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflicts of interest C.T. was a postdoctoral fellow on assignment at GlaxoSmithKline at the time this manuscript was written. S.F., W.S., R.P., and S.P. are employees of and own stock in GlaxoSmithKline."

Evidence found in paper:

"Financial support and sponsorship This work was supported by ViiV Healthcare."

Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025